Search

Your search keyword '"Moreau, P."' showing total 20 results
Start Over Author "Moreau, P." Journal annals of oncology
20 results on '"Moreau, P."'

3. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P., Anderson, K.C., Attal, M., Richardson, P.G., Badros, A., Hou, J., Comenzo, R., Du, J., Durie, B.G.M., San Miguel, J., Einsele, H., Chen, W.M., Garderet, L., Pietrantuono, G., Hillengass, J., Kyle, R.A., Moreau, P., Lahuerta, J.J., Landgren, O., Ludwig, H., Larocca, A., Mahindra, A., Cavo, M., Mazumder, A., McCarthy, P.L., Nouel, A., Rajkumar, S.V., Reiman, A., Riva, E., Sezer, O., Terpos, E., Turesson, I., Usmani, S., Weiss, B.M., and Palumbo, A.

Published
2017
Full Text
View/download PDF

4. Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma

Author

Fouquet, G., Pegourie, B., Macro, M., Petillon, M.O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., Kolb, B., Stoppa, A.M., Brechiniac, S., Richez, V., Rodon, P., Banos, A., Wetterwald, M., Garderet, L., Royer, B., Hulin, C., Benbouker, L., Decaux, O., Escoffre-Barbe, M., Fermand, J.P., Attal, M., Avet-Loiseau, H., Moreau, P., Facon, T., and Leleu, X.

Published
2016
Full Text
View/download PDF

6. Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”

Author

Dimopoulos, M.A., primary, Moreau, P., additional, Terpos, E., additional, Mateos, M.V., additional, Zweegman, S., additional, Cook, G., additional, Delforge, M., additional, Hájek, R., additional, Schjesvold, F., additional, Cavo, M., additional, Goldschmidt, H., additional, Facon, T., additional, Einsele, H., additional, Boccadoro, M., additional, San-Miguel, J., additional, Sonneveld, P., additional, and Mey, U., additional

Published
2022
Full Text
View/download PDF

7. VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Author

Moreau, P., primary, Dimopoulos, M.A.C., additional, Mikhael, J., additional, Yong, K., additional, Capra, M., additional, Facon, T., additional, Hajek, R., additional, Špička, I., additional, Casca, F., additional, Mace, S., additional, Singh, E., additional, Risse, M-L., additional, and Martin, T., additional

Published
2022
Full Text
View/download PDF

11. Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’

Author

Dimopoulos, M.A., primary, Moreau, P., additional, Terpos, E., additional, Mateos, M.V., additional, Zweegman, S., additional, Cook, G., additional, Delforge, M., additional, Hájek, R., additional, Schjesvold, F., additional, Cavo, M., additional, Goldschmidt, H., additional, Facon, T., additional, Einsele, H., additional, Boccadoro, M., additional, San-Miguel, J., additional, Sonneveld, P., additional, and Mey, U., additional

Published
2022
Full Text
View/download PDF

13. Progression of disease within 2 years (POD24) is a clinically significant endpoint to identify follicular lymphoma patients with high risk of death

Author

Sortais, C., primary, Lok, A., additional, Gastinne, T., additional, Mahé, B., additional, Dubruille, V., additional, Blin, N., additional, Howlett, S., additional, Tabah, A., additional, Arnaud, P., additional, Moreau, A., additional, Moreau, P., additional, Leux, C., additional, and Le Gouill, S., additional

Published
2018
Full Text
View/download PDF

14. Second primary malignancies in multiple myeloma: an overview and IMWG consensus

Author

Musto, P., primary, Anderson, K.C., additional, Attal, M., additional, Richardson, P.G., additional, Badros, A., additional, Hou, J., additional, Comenzo, R., additional, Du, J., additional, Durie, B.G.M., additional, San Miguel, J., additional, Einsele, H., additional, Chen, W.M., additional, Garderet, L., additional, Pietrantuono, G., additional, Hillengass, J., additional, Kyle, R.A., additional, Moreau, P., additional, Lahuerta, J.J., additional, Landgren, O., additional, Ludwig, H., additional, Larocca, A., additional, Mahindra, A., additional, Cavo, M., additional, Mazumder, A., additional, McCarthy, P.L., additional, Nouel, A., additional, Rajkumar, S.V., additional, Reiman, A., additional, Riva, E., additional, Sezer, O., additional, Terpos, E., additional, Turesson, I., additional, Usmani, S., additional, Weiss, B.M., additional, and Palumbo, A., additional

Published
2018
Full Text
View/download PDF

15. Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX

Author

Moreau, P., primary, Rabin, N., additional, Plesner, T., additional, Weisel, K., additional, Sonneveld, P., additional, Mateos, M-V., additional, Schecter, J.M., additional, Amin, H., additional, Trivedi, S., additional, and Dimopoulos, M.A., additional

Published
2017
Full Text
View/download PDF

20. Multiple myeloma

Author

Jesús F. San-Miguel, U. Mey, Mario Boccadoro, Thierry Facon, Roman Hájek, P. Moreau, M.V. Mateos, E. Terpos, M.A. Dimopoulos, Michele Cavo, Fredrik Schjesvold, H. Goldschmidt, Gordon Cook, Michel Delforge, Sonja Zweegman, H. Einsele, Pieter Sonneveld, Hematology, CCA - Cancer Treatment and quality of life, Dimopoulos M.A., Moreau P., Terpos E., Mateos M.V., Zweegman S., Cook G., Delforge M., Hajek R., Schjesvold F., Cavo M., Goldschmidt H., Facon T., Einsele H., Boccadoro M., San-Miguel J., Sonneveld P., and Mey U.

Subjects
Pediatrics, medicine.medical_specialty, MINIMAL RESIDUAL DISEASE, BORTEZOMIB, THERAPY, Follow-Up Studie, CONDITIONING REGIMEN, follow-up, ORAL IXAZOMIB, Medicine, Multiple myeloma, Societies, Medical, Science & Technology, treatment, INTERGROUPE FRANCOPHONE, business.industry, Follow up studies, STEM-CELL TRANSPLANTATION, Hematology, Guideline Article - Consensus based, medicine.disease, OPEN-LABEL, PHASE-III, Clinical Practice, multiple myeloma, diagnosi, Oncology, Diagnosis treatment, business, Life Sciences & Biomedicine, clinical practice guideline, prognosi, LENALIDOMIDE PLUS DEXAMETHASONE, Human
Abstract

ispartof: HEMASPHERE vol:5 issue:2 ispartof: location:United States status: published

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results